small molecule

INVOKANA

CANAGLIFLOZIN

Loss of exclusivityAugust 2029latest FDA-listed patent expiry

CompanyJanssen Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand name	INVOKANA
Active ingredient	CANAGLIFLOZIN
Strength	300MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	March 2013
Marketing status	RX

Listed patents

Patent	Expires	Type
7943582*PED	August 2029	—
7943582	February 2029	substance, product
8513202*PED	June 2028	—
7943788*PED	January 2028	—
8513202	December 2027	substance, product
7943788	July 2027	substance, product

Regulatory exclusivity

Code	Expires
PED	June 2028
NPP	December 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Janssen Pharmaceuticals